BIOAGE LABS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
BIOAGE LABS, INC. (BIOA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$16.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-24
- BIOAGE LABS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$16.93M.
- BIOAGE LABS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$14.94M.
- BIOAGE LABS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$13.41M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$16.93M 10-K · filed 2026-03-24 |
| 2024-12-31 | -$14.94M 10-K · filed 2026-03-24 |
| 2023-12-31 | -$13.41M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |